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Abstract
Background—It is unclear whether blood pressure control varies across the spectrum of 
atherosclerotic risk.
Methods—We used data from nonpregnant adults who had fasted laboratory samples drawn for 
the 2007-2009 cycle of the Canadian Health Measures Survey (CHMS) or the 2005-2008 US 
National Health and Nutrition Examination Survey (NHANES).
Results—The 1692 CHMS subjects and 3541 NHANES participants were demographically 
similar (aged a mean of 45 years), although NHANES participants exhibited higher obesity rates 
(33.8% vs 22.2%, P < 0.001). Over 80% of CHMS and NHANES subjects with hypertension had 
at least 1 other cardiovascular risk factor. As the number of atherosclerotic risk factors increased, 
hypertension prevalence increased, but blood pressure control rates improved (from 48% among 
hypertensives with no other risk factors in CHMS to 77% among those with 3 or more risk factors, 
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and from 35% to 53% in NHANES). However, the converse was not true: The distribution of 
Framingham risk scores for those subjects with “controlled hypertension” was nearly identical to 
the distribution among those adults with uncontrolled hypertension in both CHMS and NHANES 
and substantially higher than scores in normotensive subjects.
Conclusions—Although control of blood pressure was better in patients with multiple 
atherosclerotic risk factors, hypertensives with controlled blood pressures exhibited risk-factor 
profiles similar to those of participants with uncontrolled blood pressures. This suggests the need, 
in educational messaging and therapy decision making, for an increased focus on total 
atherosclerotic risk rather than just blood pressure control.
Cardiovascular (CV) guidelines and continuing medical education activities have 
traditionally emphasized the treatment and attainment of “target levels” for individual risk 
factors such as hypertension, dyslipidemia, or dysglycemia.1 Although it has long been 
recognized that an individual’s absolute CV risk depends on the level of each of their CV 
risk factors,2-7 the interplay between multiple CV risk factors and their control rates is 
unclear in Canadian and US adults. While some studies have demonstrated that hypertensive 
patients with poorly controlled blood pressure but multiple comorbidities were less likely to 
have their antihypertensive therapy intensified,8 others have reported better blood pressure 
control and treatment intensification rates in those with multiple comorbidities.9 However, 
prior studies have focused on patients attending physician clinics and having discrete 
comorbidities (such as angina, chronic pulmonary disease, arthritis, depression, or diabetes), 
and it is unknown whether adults with other CV risk factors are more or less likely to have 
their blood pressure (BP) treated and controlled. We designed this study to explore whether 
BP control rates differed by CV risk profiles in nationally representative samples of 
individuals from Canada and the United States and to examine the extent to which other CV 
risk factors are optimized in Canadian and US adults with and without hypertension.
Methods
We used 2 North American population-based surveys that randomly sampled (using 
complex, multistage probability sampling) community-dwelling individuals, employed 
similar face-to-face questionnaires to ascertain medical history and medication use, 
measured physical attributes such as body mass index and BP levels, and collected fasting 
laboratory samples in a random sample of participants. The methodologies of cycle 1 of the 
Canadian Health Measures Survey (CHMS) 2007-2009 and the US National Health And 
Nutrition Examination Survey (NHANES) 2005-2008 have been described in full 
elsewhere.10-12
The NHANES collected up to 3 BP measurements with manual mercury 
sphygmomanometers, and for this analysis we averaged the second and third BP 
measurement in each subject. In the CHMS, BP was measured with an electronic 
oscillometric monitor (the BpTRU device, BpTRU Medical Devices Ltd, Coquitlam, British 
Columbia), and 6 readings were taken, with the last 5 averaged to determine the BP reading 
for each respondent. Although for this report we used the BpTRU measures for CHMS 
participants, in a prior publication12 we reported control rates after converting BpTRU 
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measurements to manual sphygmomanometer estimates using a previously validated linear 
regression equation.13
We limited our analyses to participants aged 20 to 79 years with at least 2 BP measurements 
and excluded any subjects who were pregnant. We defined hypertension as being present if a 
subject had mean systolic BP (SBP) ≥ 140 mm Hg and/or mean diastolic BP (DBP) ≥ 90 
mm Hg (or mean SBP ≥ 130 mm Hg and/or DBP ≥ 80 mm Hg in those with diabetes 
mellitus in a sensitivity analysis) and/or self-reported current use of BP-lowering medication 
or health care provider–assigned diagnosis of hypertension. We defined study participants 
with hypertension as having “controlled” BP if their SBP was < 140 mm Hg and their DBP 
was < 90 mm Hg (< 130/80 mm Hg for those with diabetes in a sensitivity analysis).
While prior studies of risk factors have used patient self-report to classify patients, we a 
priori decided to include fasting laboratory samples and medication reviews to derive “gold 
standard” case definitions for each of the CV risk factors we considered. For example, we 
classified a patient as having dyslipidemia if the patient had fasting low-density lipoprotein 
cholesterol ≥ 3.5 mmol/L plus elevated ratio of total to high-density lipoprotein cholesterol 
(≥ 5.5 among men, ≥ 4.5 among women) or if the patient was a current user of lipid-
lowering medications. Other case definitions are given in the footnote to Table 1.14,15 We 
estimated each subject’s risk of incident CV disease (coronary death, nonfatal myocardial 
infarction, angina, stroke or transient ischemic attack, peripheral arterial disease, or heart 
failure) using the Framingham 10-year general CV risk prediction equation for those 
subjects aged between 30 and 74 years.16 We calculated the crude score for each subject and 
compared between patients with hypertension (controlled vs uncontrolled) and without 
hypertension.
Survey weights were applied to the CHMS results according to Statistics Canada CHMS 
Data User Guide: Cycle 1 (http://www.statcan.gc.ca/imdb-bmdi/document/
5071_D2_T1_V1-eng.pdf). The weighted CHMS data were analyzed with SAS software 
(Enterprise Guide Version 4.1, SAS Institute Inc, Cary, NC). All NHANES analyses were 
conducted with the SUDAAN software package, which incorporates the survey’s complex 
sample design and the fasting sample weights, according to the NHANES Analytic and 
Reporting Guidelines (http://www.cdc.gov/nchs/nhanes/nhanes2003-2004/
analytical_guidelines.htm).
Results
We analyzed data from 1692 CHMS participants and 3541 NHANES participants aged 20 to 
79 years, not pregnant, had at least 2 BP readings, and had fasting blood work done (Fig. 1). 
The household response rates for the 2 surveys were comparable (70% in CHMS and 76% in 
NHANES).
The CHMS (Table 1) and NHANES (Table 2) subjects were demographically similar and 
exhibited similar serum creatinine and fasting lipid profiles; however, NHANES participants 
were more likely to be obese (33.8% vs 22.2%, P < 0.001) or diabetic (11.1% vs 6.9%, P < 
0.001) and had higher mean SBP (120 mm Hg vs 112 mm Hg, P < 0.001), body mass index 
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(28.5 vs 27.0), and fasting serum glucose (5.8 mmol/L vs 5.1 mmol/L). Even after adjusting 
the CHMS BpTRU measurements to estimate manual sphygmomanometer readings (115.5 
mm Hg with 95% confidence interval (CI) of 114.1-117.0 mm Hg), there was still a 
statistically significant difference between mean SBP in the Canadian and US samples (P < 
0.001). There was no evidence of systematic bias in the 2 surveys between those who did 
and did not have fasting blood work done (data not shown). Of the 3541 fasted subjects in 
NHANES, 735 (21%) were at low CV risk (men younger than 55 years or women younger 
than 60 years without hypertension, target organ damage, or other atherosclerotic risk 
factors); 515 (30%) of the 1692 fasted CHMS subjects met the same definition of low CV 
risk.
Comparing subject self-report with the gold-standard case definitions we used in this 
analysis (based on laboratory measurements plus review of prescribed medications plus self-
report), we found that although self-report by itself was reasonably accurate for diabetes 
mellitus (k, 0.73 [95% CI, 0.67-0.77]; sensitivity, 64% [95% CI, 59%-67%]; specificity, 
99.5% [95% CI, 99.1%-99.7%]), self-report was considerably less accurate for dyslipidemia 
(k, 0.52 [95% CI, 0.47-0.57]; sensitivity, 69% [95% CI, 65%-72%]; specificity, 83% [95% 
CI, 82%-85%]) and chronic kidney disease (k, 0.08 [95% CI, 0.47-0.57]; sensitivity, 7% 
[95% CI, 5%-8%]; specificity, 99% [95% CI, 98%-99%]). This finding supported our 
decision to use case definitions that relied on more than just self-report in the analyses 
outlined below.
Hypertensive individuals were more likely to have other CV risk factors or target organ 
damage than were normotensive subjects in both CHMS and NHANES (Tables 1 and 2). 
Overall, 81% of hypertensive CHMS subjects (76% of those with controlled BPs and 85% 
of those with uncontrolled BPs) and 85% of hypertensive NHANES participants (88% of 
those with controlled BPs and 83% of those with uncontrolled BPs) had at least 1 other CV 
risk factor (compared with 49% and 60% of their normotensive peers, both P < 0.001). 
Target organ damage was more common in hypertensive participants in both surveys, 
particularly chronic kidney disease (21% vs 8% in CHMS and 20% vs 6% in NHANES, 
both P < 0.001); indeed, chronic kidney disease was more common than CV disease among 
these community-dwelling hypertensive participants. Of all 459 fasted hypertensive 
participants in CHMS, only 30 (7%) could be classified as “lower-risk hypertensives” (men 
younger than 55 years or women younger than 60 years without target organ damage or 
other risk factors, and with SBP < 160 mm Hg and DBP < 100 mm Hg). Of the 1422 fasted 
hypertensive subjects in NHANES, only 100 (7%) fit the same definition of “lower-risk 
hypertensives.”
Hypertension prevalence, treatment, and control rates differed substantially across patient 
subgroups defined by comorbidity profiles (Figs. 2A and 2B). Although BP control rates 
were generally higher in Canada (59% if goal BP was defined as < 140/90 mm Hg in all 
patients and 55% if goal BP was defined as < 130/80 mm Hg in those with diabetes and < 
140/90 mm Hg in all others) than in the United States (44% if goal BP was defined as < 
140/90 mm Hg in all patients and 36% if goal BP was defined as < 130/80 mm Hg in those 
with diabetes and < 140/90 mm Hg in all others), the relative patterns were similar in 
Canada and the United States in that while those with overt CV disease, diabetes, or 
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dyslipidemia exhibited the highest rates of BP treatment and control, those with 
hypertension and no other CV risk factors or who smoked or had chronic kidney disease 
exhibited the lowest rates of control. As the number of concomitant CV risk factors 
increased, hypertension prevalence increased in both Canada and the United States, as did 
the proportion of hypertensive individuals who were controlled (Figs. 3A and 3B).
Although hemoglobin A1c, fasting glucose, and body mass index were significantly lower in 
normotensive subjects than in hypertensive individuals in both surveys, there were no 
appreciable differences among those with hypertension who had controlled vs uncontrolled 
BPs in these risk factors or others such as cholesterol levels or serum creatinines in either 
CHMS (Table 1) or NHANES (Table 2). Even those subjects with hypertension who were 
defined as “controlled” since they were at (or below) target BPs had substantially higher 
Framingham scores than did those subjects without hypertension (Table 3). Indeed, the 
distribution of Framingham risk scores for the “controlled hypertension” subjects was nearly 
identical to the distribution among those adults with hypertension who were uncontrolled in 
both CHMS and NHANES (Table 3).
Discussion
Our study confirms that even at the end of the first decade of the 21st century, more than 
80% of Canadian and US adults with hypertension have at least 1 other CV risk factor and 
that hypertension prevalence increased as the number of atherosclerotic risk factors 
increased. This is consistent with data from the Reduction of Atherothrombosis for 
Continued Health (REACH) registry17 and mirrors findings from North American 
population-based surveys and primary care medical record audits from earlier decades.18-20 
However, our more important finding was that despite concerns that patients with multiple 
comorbidities may have their BP less well treated,8 we found that BP control rates actually 
improved as the number of other risk factors increased in both Canada and the United States. 
This pattern was also reported in medical record audits from a group of primary care 
practices in Southwestern Ontario in 200421 but has not been seen in other jurisdictions.22,23
Thus, while control rates for hypertension have improved markedly in both Canada12 and 
the United States24 during the past 2 decades, the persistently high prevalence of additional 
CV risk factors in hypertensive individuals will blunt the potential magnitude of the 
reductions in CV morbidity and mortality that would have been expected otherwise. Indeed, 
although other atherosclerotic risk factors were more common in hypertensive than in 
normotensive individuals, we found that subjects with controlled hypertension did not 
exhibit any better control of their other risk factors, with the exception of current smoking, 
than did those with uncontrolled hypertension. As a result, even those hypertensive 
individuals with BPs controlled to guideline-recommended target levels still exhibited 
substantially higher Framingham risk scores for subsequent CV disease than did 
normotensive individuals in both surveys. Previous studies have also reported that treated 
hypertensives have poorer CV prognoses than do untreated normotensives with the same 
BPs.25-27 Analyses of the NHANES III Linked Mortality File28 and the Investigations 
Preventives et Cliniques cohort29 suggested that this was a result of undertreatment of their 
other atherosclerotic risk factors.
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Although our study comparing data from the most recent cycles of the CHMS and NHANES 
has many strengths, it is not without limitations. A particular strength of our study was the 
use of fasting laboratory measurements and review of medication profiles to supplement 
self-report in identifying CV risk factors. Thus, although we found higher rates for all CV 
risk factors than reported in recent papers that relied on self-report alone,30 we likely still 
underestimated the prevalence of multiple atherosclerotic risk factors in hypertensive 
individuals since both the CHMS and NHANES excluded institutionalized adults and older 
persons living in nursing homes who do have higher comorbidity burdens than community-
dwelling adults.31 Restriction of our analysis to those survey participants who provided 
fasting blood work resulted in slightly different estimates of hypertension prevalence, 
treatment, and control rates than those in prior CHMS publications.10,12 While the 
Framingham equations have been validated in North American populations and can 
discriminate which patients are at elevated risk, their accuracy in estimating absolute CV 
event rates is still debated.32 As such, in this paper we reported only the crude scores for 
those subjects aged 30 to 74 years in both CHMS and NHANES, rather than trying to 
convert those scores to estimated event rates.
In conclusion, mortality rates (both all-cause and CV) are directly related to the number of 
poorly controlled CV risk factors in Canadian and US adults.5 While others have reported 
that less than 1% of American adults exhibit ideal CV health,33,34 our study expands on 
these earlier reports by focusing on the issue of CV health in community-dwelling 
hypertensive individuals. Our important finding was that although hypertensive individuals 
with multiple risk factors exhibited better BP control rates than did individuals with 
uncomplicated hypertension, the converse was not true: hypertensive individuals with BPs 
controlled below target levels recommended in guidelines still had Framingham absolute 
risk scores that were not appreciably different than those with uncontrolled BP levels. 
Although educational programs appear to have been successful in improving BP control 
rates, future efforts need to expand beyond the focus on BP levels to address all 
atherosclerotic risk factors in hypertensive individuals.35
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Figure 1. 
Derivation of both samples. BP, blood pressure; NHANES, National Health and Nutrition 
Examination Survey.
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Figure 2. 
(A) Hypertension (HTN) prevalence, treatment, and control in Canadian Health Measures 
Survey participants, stratified by risk factors. Risk-factor groups are not mutually exclusive. 
Blood pressure (BP) control was defined as < 140/90 mm Hg in all groups. If definition of 
BP control is lowered to < 130/80 mm Hg in subjects with diabetes mellitus, the proportion 
with HTN treated and controlled is 54.6% and the proportion with HTN uncontrolled is 
45.5%. (B) HTN prevalence, treatment, and control in National Health and Nutrition 
Examination Survey participants, stratified by risk factors. Risk-factor groups are not 
mutually exclusive. BP control was defined as < 140/90 mm Hg in all groups. If definition 
of BP control is lowered to < 130/80 mm Hg in subjects with diabetes mellitus, the 
proportion with HTN treated and controlled is 26% and the proportion with HTN 
uncontrolled is 52%. CKD, chronic kidney disease; CV, cardiovascular; DM, diabetes 
mellitus.
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Figure 3. 
(A) Hypertension (HTN) prevalence, treatment, and control in Canadian Health Measures 
Survey participants, stratified by number of other cardiovascular risk factors. Cardiovascular 
risk factors include smoking, obesity, diabetes mellitus, dyslipidemia, and chronic kidney 
disease (7 patients excluded from this figure because of missing data in at least 1 of these 
fields). (B) HTN prevalence, treatment, and control in National Health and Nutrition 
Examination Survey participants, stratified by number of other cardiovascular risk factors. 
Cardiovascular risk factors include smoking, obesity, diabetes mellitus, dyslipidemia, or 
chronic kidney disease.
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Table 3
Framingham risk score distribution by hypertension status in individuals aged 30 to 74 years
CHMS NHANES
n Mean 95% CI n Mean 95% CI
10-year general cardiovascular disease risk (lipid based)
 Including those with DM or CKD 1263 7.6 7.1-8.0 2760 9.8 9.1-10.6
  Treated and controlled hypertension 183 14.4 12.3-16.5 530 14.5 13.1-15.8
  Nonhypertensive 942 5.5 5.1-5.8 1527 6.0 5.5-6.6
  Uncontrolled, untreated, or unaware hypertension 138 15.9 11.6-20.2 703 16.7 15.4-18.0
 Excluding those with DM or CKD 1065 6.7 6.3-7.0 2000 7.7 7.1-8.2
  Treated and controlled 112 13.2 11.3-15.2 289 11.3 10.0-12.6
  Nonhypertensive 852 5.1 4.7-5.4 1290 5.5 5.0-6.1
  Uncontrolled, untreated, or unaware 101 14.9 10.2-19.7 421 12.5 11.5-13.5
10-year general cardiovascular disease risk (BMI based)
 Including those with DM or CKD 1261 9.0 8.5-9.5 2747 12.2 11.2-13.2
  Treated and controlled 183 18.5 16.5-20.6 527 19.7 17.8-21.6
  Nonhypertensive 940 6.1 5.7-6.5 1522 7.1 6.6-7.7
  Uncontrolled, untreated, or unaware 138 20.2 14.8-25.5 698 20.3 18.7-21.9
 Excluding those with DM or CKD 1064 8.0 7.5-8.5 1995 9.3 8.6-10.0
  Treated and controlled 112 17.0 15.0-19.0 287 15.1 13.7-16.6
  Nonhypertensive 851 5.8 5.4-6.2 1289 6.5 5.9-7.1
  Uncontrolled, untreated, or unaware 101 19.2 13.2-25.2 419 14.8 13.6-16.0
For Framingham equation, diabetes is defined as self-reported diabetes medication use OR fasting plasma glucose > 7 mmol/L.
CHMS, Canadian Health Measures Survey; CI, confidence interval; CKD, chronic kidney disease; DM, diabetes mellitus; NHANES, National 
Health and Nutrition Examination Survey.
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